Literature DB >> 30843143

Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer's Disease.

Stephen M Day1,2, Tao Ma3,4,5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30843143      PMCID: PMC6754471          DOI: 10.1007/s12264-019-00355-y

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


× No keyword cloud information.
  20 in total

Review 1.  Minireview: the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

2.  Synaptic stimulation of mTOR is mediated by Wnt signaling and regulation of glycogen synthetase kinase-3.

Authors:  Tao Ma; Nikos Tzavaras; Panayiotis Tsokas; Emmanuel M Landau; Robert D Blitzer
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 3.  GSK3 in Alzheimer's disease: mind the isoforms.

Authors:  Tao Ma
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 4.  Alzheimer's disease: the challenge of the second century.

Authors:  David M Holtzman; John C Morris; Alison M Goate
Journal:  Sci Transl Med       Date:  2011-04-06       Impact factor: 17.956

Review 5.  Glucagon-like peptide 1 in health and disease.

Authors:  Andreas Andersen; Asger Lund; Filip K Knop; Tina Vilsbøll
Journal:  Nat Rev Endocrinol       Date:  2018-07       Impact factor: 43.330

6.  Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

Authors:  Talib Abbas; Emilie Faivre; Christian Hölscher
Journal:  Behav Brain Res       Date:  2009-06-30       Impact factor: 3.332

7.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.

Authors:  Matthew J During; Lei Cao; David S Zuzga; Jeremy S Francis; Helen L Fitzsimons; Xiangyang Jiao; Ross J Bland; Matthias Klugmann; William A Banks; Daniel J Drucker; Colin N Haile
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

8.  A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.

Authors:  Tian Li; Juan-Juan Jiao; Christian Hölscher; Mei-Na Wu; Jun Zhang; Jia-Qing Tong; Xue-Fan Dong; Xue-Song Qu; Yue Cao; Hong-Yan Cai; Qiang Su; Jin-Shun Qi
Journal:  Hippocampus       Date:  2018-03-05       Impact factor: 3.899

9.  LTP inhibits LTD in the hippocampus via regulation of GSK3beta.

Authors:  Stéphane Peineau; Changiz Taghibiglou; Clarrisa Bradley; Tak Pan Wong; Lidong Liu; Jie Lu; Edmond Lo; Dongchuan Wu; Emilia Saule; Tristan Bouschet; Paul Matthews; John T R Isaac; Zuner A Bortolotto; Yu Tian Wang; Graham L Collingridge
Journal:  Neuron       Date:  2007-03-01       Impact factor: 17.173

Review 10.  The GSK3 hypothesis of Alzheimer's disease.

Authors:  Claudie Hooper; Richard Killick; Simon Lovestone
Journal:  J Neurochem       Date:  2007-12-18       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.